M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 44 of 54

COMPLETED

Registry for Women Who Are At Risk Or May Have Lynch Syndrome

NCT00508573
TERMINATED Phase 1

Proton Therapy and Bevacizumab for Primary Liver Tumors

NCT00426829
TERMINATED Phase 1

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

NCT00473551
TERMINATED Phase 1

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

NCT00477503
COMPLETED Phase 1

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

NCT00501410
COMPLETED Phase 1

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

NCT00477412
COMPLETED

Health and Cancer Issues in the South Asian Community

NCT00479830
COMPLETED Phase 2

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

NCT00478361
COMPLETED

Spectral Diagnosis of Cutaneous Malignancy

NCT00476905
COMPLETED Phase 2

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

NCT00449748
COMPLETED

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

NCT00453661
COMPLETED Phase 2

Catheter Related - Gram Positive Bloodstream Infections

NCT00467272
COMPLETED Phase 2

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

NCT00465179
COMPLETED

Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among HSCT Patients

NCT00429455
COMPLETED Phase 2

Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

NCT00429507
COMPLETED

Fatigue Experience in Cancer Patients

NCT00450541
TERMINATED Phase 2

Biochemotherapy With Temozolomide for Metastatic Melanoma

NCT00505635
TERMINATED NA

3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate

NCT00464724
COMPLETED Phase 2

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

NCT00439556
COMPLETED

Oral Margin Spectroscopy Detection Using Optical Spectroscopy

NCT00439205
COMPLETED Phase 1

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

NCT00439361
COMPLETED NA

Cancer Genetics CD-ROM for Hispanics

NCT00525980
COMPLETED Phase 2

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00448019
COMPLETED Phase 1

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

NCT00431054
COMPLETED Phase 1

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

NCT00436657
COMPLETED NA

Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers

NCT00432471
COMPLETED Phase 2

Methylphenidate and a Nursing Telephone Intervention for Fatigue

NCT00424099
COMPLETED NA

Parenteral Hydration in Advanced Cancer Patients

NCT00423722
COMPLETED

Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

NCT00837499
COMPLETED Phase 2

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

NCT00485485
COMPLETED Phase 1

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

NCT00428545
COMPLETED

Using Focus Groups to Assess the Impact of Environmental Health Science Programs for K-12 Educational Community

NCT00428402
COMPLETED

Development of the MDASI-Spine Tumor Module

NCT00430872
COMPLETED

Combined Strength Training and Functional Endurance Exercise Regimen on Cancer -Related Fatigue and Physical Performance

NCT00421057
COMPLETED Phase 3

Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

NCT00112996
COMPLETED Phase 1

Gemcitabine and Dasatinib in Advanced Solid Tumors

NCT00429234
TERMINATED NA

3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate

NCT00429338
TERMINATED Phase 2

Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

NCT00432445
TERMINATED

Effectiveness of Protected Environment Rooms for AML and MDS

NCT00443300
TERMINATED Phase 1

Voraxaze for Delayed Methotrexate Clearance

NCT00424645
TERMINATED Phase 2

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

NCT00414076
COMPLETED Phase 2

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

NCT00413166
COMPLETED Phase 2

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT00414310
COMPLETED NA

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

NCT00410488
COMPLETED Phase 1

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

NCT00410982
COMPLETED Phase 2

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

NCT00422591
COMPLETED NA

Effect on Clip Markers After Vacuum-Assisted Biopsy by Postprocedure Mammogram

NCT00529737
TERMINATED Phase 2

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

NCT00415857
TERMINATED Phase 1

Thymoglobulin (ATG) Dose Finding Study

NCT00409695
TERMINATED Phase 2

Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment

NCT00409331
← Previous Page 44 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.